Global Urinary Tract Infection Market 2025-2035

Description

List of Tables

Global Urinary Tract Infection Market Size, Share & Trends Analysis by Test Type (Biochemical, Microscopic, and Flow Cytometric), by Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection, and Neurogenic Bladder Infections), and by End User (Hospitals and Clinics, and Home Healthcare) Forecast Period (2025-2035)

Industry Overview

Urinary tract infection market was valued at $12.8 billion in 2024 and is projected to reach $19.5 billion by 2035, growing at a CAGR of 3.9% during the forecast period (2025-2035). The market is driven by factors including the rising incidence of UTIs due to lifestyle changes and chronic conditions like diabetes, advancements in diagnostic technologies, and increasing healthcare expenditure and infrastructure. Additionally, a growing emphasis on antimicrobial resistance and the development of new treatments and testing methods are significant market drivers.

Market Dynamics

Rising Incidence, Aging Populations, And Expanding Outpatient Care

Global UTI incidence remains high, especially among women and older adults, and an aging population with more comorbidities (catheterization, diabetes, neurogenic bladder) increases recurrent and complicated UTI cases that require diagnostic follow-up and advanced care. Growth in outpatient management, telemedicine, and home health also drives demand for rapid POC and at-home urinalysis kits, expanding volumes in low-cost biochemical testing even as labs modernize. These demographic and care-delivery trends underpin steady baseline volume growth across diagnostics and treatments.

Antimicrobial Resistance (AMR) And Therapeutic Innovation

Rising AMR among common UTI pathogens (notably E. coli) is forcing clinicians to rely more on accurate diagnostics and new treatment options. AMR concerns increase demand for rapid susceptibility testing, molecular panels that identify resistance markers, and novel antibiotics. Regulatory approvals of new agents (for example, GSK's gepotidacin approval for uncomplicated UTI) both address an urgent clinical need and stimulate market activity -drawing investment into R&D, changing prescribing patterns, and expanding the commercial opportunity for pharmaceutical players.

Technological Innovation And Laboratory Automation

Advances in automated urine particle analysis (flow cytometry), digital microscopy, integrated POC platforms, and molecular multiplex panels are shifting market share from manual microscopy and culture toward rapid, automated triage and testing. Automation improves throughput, reduces turnaround times, and lowers unnecessary culture costs -attractive to hospital labs and large reference labs. Simultaneously, digital health integration (smartphone-linked tests, telehealth workflows) expands the at-home testing market. These technology trends are the primary reason diagnostics subsegments (flow cytometry, molecular) report the highest CAGRs in recent studies.

Market Segmentation

Based on the test type, the market is segmented into biochemical, microscopic, and flow cytometric.
Based on the indication, the market is segmented into complicated urinary tract infections, uncomplicated urinary tract infections, and neurogenic bladder infections.
Based on the end-user, the market is segmented into hospitals and clinics, and home healthcare.

Biochemical Segment to Grow at a Considerable Market Share

Among all segments, the biochemical test type segment holds the largest share in the Global Urinary Tract Infection Market. This dominance is attributed to the widespread use of biochemical urinalysis test strips and reagent-based analyzers in hospitals, clinics, and home settings for rapid and cost-effective detection of UTIs. Biochemical urinalysis involves testing urine samples for parameters such as leukocyte esterase, nitrites, protein, glucose, and pH critical indicators for infection diagnosis. The test's simplicity, affordability, and ability to deliver results within minutes make it indispensable in both developed and emerging economies. In addition, biochemical testing forms the first line of screening before confirmatory laboratory analyses, sustaining its demand across diagnostic workflows. The segment benefits from strong recurring revenues through reagent and consumable sales, as most facilities perform these tests daily.

Moreover, technological advancements such as semi-automated and fully automated urine analyzers with improved digital interfaces and connectivity to hospital information systems have strengthened this segment's position. The adoption of smart urinalysis devices and smartphone-based dipstick readers for home use has further expanded the market reach. Consequently, the Biochemical segment is projected to maintain its lead throughout the forecast period due to its cost-effectiveness, diagnostic accuracy, and adaptability across clinical and home healthcare environments.

Complicated Urinary Tract Infection: A Key Segment in Market Growth

Among the various indications, complicated urinary tract infection (cUTI) stands out as the key segment driving growth in the global urinary tract infection market. This segment is witnessing robust expansion due to the increasing prevalence of catheter-associated infections, recurrent UTIs, and infections linked to structural or functional urinary tract abnormalities, particularly among the elderly and hospitalized patients. The rising incidence of comorbidities such as diabetes, chronic kidney disease, and neurogenic bladder conditions further amplifies the risk of cUTI, necessitating advanced diagnostic and therapeutic approaches. Hospitals and clinics remain the major end-users for cUTI diagnosis and treatment, owing to the requirement for laboratory-based tests, hospitalization, and intravenous antibiotic therapy.

Moreover, antimicrobial resistance (AMR) has intensified the complexity of treating cUTIs, leading to a growing demand for novel antibiotics, precision diagnostics, and susceptibility testing. Pharmaceutical companies and diagnostic manufacturers are focusing on developing advanced solutions to tackle resistant pathogens -for instance, GSK's gepotidacin, recently approved for UTI treatment, marks a major step in combating resistance-driven infections. As a result, hospitals are adopting automated urine analyzers, flow cytometry systems, and molecular diagnostic tools for faster pathogen detection and targeted therapy decisions. While uncomplicated UTI cases drive high-volume biochemical testing, the cUTI segment's need for specialized, high-value diagnostic and therapeutic products positions it as the fastest-growing revenue contributor in the overall market. Its growth is further supported by government initiatives promoting antibiotic stewardship and technological advancements in diagnostic platforms.

Regional Outlook

The global urinary tract infection market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US holds the largest share in the global urinary tract infection (UTI) market, driven by a high disease prevalence, advanced healthcare infrastructure, and rapid adoption of diagnostic and therapeutic innovations. With millions of UTI-related consultations each year, the U.S. represents the most mature and lucrative market for both diagnostics and treatment. Leading diagnostic providers such as Quest Diagnostics and Labcorp, along with top manufacturers like Roche, Abbott, and Siemens Healthineers, have established a strong presence, offering advanced urinalysis analyzers, flow cytometry systems, and molecular diagnostic platforms.

The US additionally leads in pharmaceutical advancements, with major players such as GlaxoSmithKline (GSK), Pfizer, and Johnson & Johnson investing in novel antibiotics to combat antimicrobial resistance. The FDA's recent approval of GSK's gepotidacin for uncomplicated UTIs highlights the nation's focus on innovative, targeted treatments. Moreover, the growing use of telemedicine and at-home diagnostic kits has increased accessibility and early detection rates. Favorable reimbursement policies, strong R&D investments, and the presence of technologically advanced laboratories further reinforce the US leadership.

Market Players Outlook

The major companies operating in the global urinary tract infection market include Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline(GSK) plc, and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

In September 2025, Huena, India's first non-antibiotic drug to combat urinary tract infections (UTIs), marked a significant step in the fight against antimicrobial resistance. UTIs are the second most common reason for antibiotic use in India, with women being more susceptible.
In March 2025, GSK approved Blujepa for treating uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients. UTIs are the most common infection in women, impacting up to 16 million women annually. New treatments are needed as drug-resistant bacteria increase, potentially leading to higher treatment failure rates.

The Report Covers:

Market value data analysis for 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global urinary tract infection market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2024040

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Urinary Tract Infection Market Sales Analysis - Test Type | Indication | End-User ($ Million)
Urinary Tract Infection Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Urinary Tract Infection Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Urinary Tract Infection Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Urinary Tract Infection Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Urinary Tract Infection Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Urinary Tract Infection Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Urinary Tract Infection Market Revenue and Share by Manufacturers
Urinary Tract Infection Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Abbott Laboratories
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bayer AG
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. F. Hoffmann-La Roche Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. GlaxoSmithKline (GSK) plc
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Pfizer Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Urinary Tract Infection Market Sales Analysis by Test Test Type ($ Million)

5.1. Biochemical Urinary Tract Infection
5.2. Microscopic Urinary Tract Infection
5.3. Flow Cytometric Urinary Tract Infection

6. Global Urinary Tract Infection Market Sales Analysis by Indication ($ Million)

6.1. Complicated Urinary Tract Infection
6.2. Uncomplicated Urinary Tract Infection
6.3. Neurogenic Bladder Infections

7. Global Urinary Tract Infection Market Sales Analysis by End-User ($ Million)

7.1. Hospitals and Clinics
7.2. Home Healthcare

8. Regional Analysis

8.1. North American Urinary Tract Infection Market Sales Analysis - Test Test Type | Indication | End-User ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Urinary Tract Infection Market Sales Analysis - Test Test Type | Indication | End-User ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Urinary Tract Infection Market Sales Analysis - Test Test Type | Indication | End-User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Urinary Tract Infection Market Sales Analysis - Test Test Type | Indication | End-User ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. F. Hoffmann-La Roche Ltd.
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Abbott Laboratories
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Danaher Corp.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Siemens Healthineers
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Thermo Fisher Scientific
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. bioMerieux
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Sysmex Corp.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Bio-Rad Laboratories
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. QIAGEN N.V.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Quest Diagnostics
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Laboratory Corp.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Cardinal Health
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. ACON Laboratories
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Randox Laboratories
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. ARKRAY Inc.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Pfizer Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. GlaxoSmithKline (GSK)
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. AstraZeneca
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Bayer AG
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Novartis International AG
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies